Starling Oncology, Inc. cash flow statement
In fiscal 2025, Starling Oncology, Inc.'s operations generated −$24.6m of cash; it spent $3.2m on capital projects, leaving free cash flow of −$27.8m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | −33 | −62 | −36 | −27 | −25 | 0 |
| Depreciation and amortisation | 3 | 3 | 4 | 6 | 6 | 7 | 7 |
| Stock-based pay | 0 | 25 | 28 | 18 | 11 | 5 | 5 |
| Capital spending | 1 | 3 | 6 | 5 | 4 | 3 | 4 |
| Free cash flow | −1 | −36 | −67 | −41 | −30 | −28 | −3 |
| Free cash flow after stock pay | −1 | −60 | −95 | −59 | −41 | −32 | −8 |
| Share buybacks | — | 0 | 9 | 1 | 0 | — | — |
| Shares issued | — | — | — | 0 | 0 | 14 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | 4 | −5 | −10 | −13 | 3 | −2 | 12 |
| Depreciation and amortisation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Stock-based pay | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Capital spending | −0 | 2 | 0 | 1 | 1 | 1 | 1 | 1 |
| Free cash flow | 1 | 2 | −5 | −11 | −13 | 2 | −3 | 11 |
| Free cash flow after stock pay | −1 | 1 | −7 | −12 | −14 | 1 | −5 | 10 |
| Shares issued | −0 | 0 | 0 | 2 | 8 | 4 | — | — |
Compare with peers
- Caredx, Inc. cash flow
- U S Physical Therapy Inc cash flow
- Corvel Corp cash flow
- Innovage Holding Corp. cash flow
- Pennant Group, Inc. cash flow
Head to head: CDNA vs STLNSTLN vs USPHCRVL vs STLN
More: Health Care Services stocks compared, Health Care sector, rankings of US companies